<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">24060865</PMID>
      <DateCompleted>
        <Year>2013</Year>
        <Month>12</Month>
        <Day>11</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1474-1768</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>13</Volume>
            <Issue>10</Issue>
            <PubDate>
              <Year>2013</Year>
              <Month>Oct</Month>
            </PubDate>
          </JournalIssue>
          <Title>Nature reviews. Cancer</Title>
          <ISOAbbreviation>Nat Rev Cancer</ISOAbbreviation>
        </Journal>
        <ArticleTitle>History of myeloid-derived suppressor cells.</ArticleTitle>
        <Pagination>
          <StartPage>739</StartPage>
          <EndPage>752</EndPage>
          <MedlinePgn>739-52</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/nrc3581</ELocationID>
        <Abstract>
          <AbstractText>Tumour-induced granulocytic hyperplasia is associated with tumour vasculogenesis and escape from immunity via T cell suppression. Initially, these myeloid cells were identified as granulocytes or monocytes; however, recent studies have revealed that this hyperplasia is associated with populations of multipotent progenitor cells that have been identified as myeloid-derived suppressor cells (MDSCs). The study of MDSCs has provided a wealth of information regarding tumour pathobiology, has extended our understanding of neoplastic progression and has modified our approaches to immune adjuvant therapy. In this Timeline article, we discuss the history of MDSCs, their influence on tumour progression and metastasis, and the crosstalk between tumour cells, MDSCs and the host macroenvironment.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Talmadge</LastName>
            <ForeName>James E</ForeName>
            <Initials>JE</Initials>
            <AffiliationInfo>
              <Affiliation>University of Nebraska Medical Center, Department of Pathology and Microbiology, 986495 Nebraska Medical Center, Omaha NE 68198-6495, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gabrilovich</LastName>
            <ForeName>Dmitry I</ForeName>
            <Initials>DI</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 CA084488</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA100062</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016456">Historical Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Nat Rev Cancer</MedlineTA>
        <NlmUniqueID>101124168</NlmUniqueID>
        <ISSNLinking>1474-175X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000943">Antigens, Differentiation</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000951">Antigens, Neoplasm</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018925">Chemokines</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000943" MajorTopicYN="N">Antigens, Differentiation</DescriptorName>
          <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000951" MajorTopicYN="N">Antigens, Neoplasm</DescriptorName>
          <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003585" MajorTopicYN="N">Cell Biology</DescriptorName>
          <QualifierName UI="Q000266" MajorTopicYN="Y">history</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019070" MajorTopicYN="N">Cell Lineage</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018925" MajorTopicYN="N">Chemokines</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006411" MajorTopicYN="N">Hematopoiesis, Extramedullary</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019650" MajorTopicYN="N">Hematopoietic Stem Cell Mobilization</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049673" MajorTopicYN="N">History, 20th Century</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049674" MajorTopicYN="N">History, 21st Century</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007955" MajorTopicYN="N">Leukemoid Reaction</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008495" MajorTopicYN="N">Medical Oncology</DescriptorName>
          <QualifierName UI="Q000266" MajorTopicYN="Y">history</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058990" MajorTopicYN="N">Molecular Targeted Therapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D039902" MajorTopicYN="N">Multipotent Stem Cells</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D022423" MajorTopicYN="N">Myeloid Cells</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D023461" MajorTopicYN="N">Myeloid Progenitor Cells</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009361" MajorTopicYN="N">Neoplasm Invasiveness</DescriptorName>
          <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009362" MajorTopicYN="N">Neoplasm Metastasis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009389" MajorTopicYN="N">Neovascularization, Pathologic</DescriptorName>
          <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047368" MajorTopicYN="N">Tumor Burden</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019139" MajorTopicYN="N">Tumor Escape</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement><b>Competing Interest Statement</b>. The authors have declared no competing financial interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">24060865</ArticleId>
        <ArticleId IdType="mid">NIHMS609367</ArticleId>
        <ArticleId IdType="pmc">PMC4358792</ArticleId>
        <ArticleId IdType="doi">10.1038/nrc3581</ArticleId>
        <ArticleId IdType="pii">nrc3581</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Sonnenfeld A. Leukamische reaktiones bei carcinoma. Zeitschrift f Klin Med. 1929;111</Citation>
        </Reference>
        <Reference>
          <Citation>Robinson WA. Granulocytosis in Neoplasia. Ann NY Acad Sci. 1965;230:212–218.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">4522870</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bennett JA, Rao VS, Mitchell MS. Systemic bacillus Calmette-Guerin (BCG) activates natural suppressor cells. Proc Natl Acad Sci U S A. 1978;75:5142–5144.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC336280</ArticleId>
            <ArticleId IdType="pubmed">283421</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Slavin S, Strober S. Induction of allograft tolerance after total lymphoid irradiation (TLI): development of suppressor cells of the mixed leukocyte reaction (MLR) J Immunol. 1979;123:942–946.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">156766</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duwe AK, Singhal SK. The immunoregulatory role of bone marrow. I. Suppression of the induction of antibody responses to T-dependent and T-independent antigens by cells in the bone marrow. Cell Immunol. 1979;43:362–371.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">314345</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brooks-Kaiser JC, Bourque LA, Hoskin DW. Heterogeneity of splenic natural suppressor cells induced in mice by treatment with cyclophosphamide. Immunopharm. 1993;25:117–129.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8500984</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fidler IJ. Tumor heterogeneity and the biology of cancer invasion and metastasis. Cancer Res. 1978;38:2651–2660.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">354778</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Porembka MR, et al.  Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth. Cancer Immunol Immunother. 2012</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3697836</ArticleId>
            <ArticleId IdType="pubmed">22215137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang L, et al.  Increased myeloid-derived suppressor cells in gastric cancer correlate with cancer stage and plasma S100A8/A9 proinflammatory proteins. J Immunol. 2013;190:794–804.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23248262</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diaz-Montero CM, et al.  Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother. 2009;58:49–59.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3401888</ArticleId>
            <ArticleId IdType="pubmed">18446337</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Younos IH, Dafferner AJ, Gulen D, Britton HC, Talmadge JE. Tumor regulation of myeloid-derived suppressor cell proliferation and trafficking. Int Immunopharmacol. 2012;13:245–256.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22609473</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Donkor MK, et al.  Mammary tumor heterogeneity in the expansion of myeloid-derived suppressor cells. Int Immunopharmacol. 2009;9:937–948.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19362167</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rashid OM, et al.  Resection of the primary tumor improves survival in metastatic breast cancer by reducing overall tumor burden. Surgery. 2013</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3664113</ArticleId>
            <ArticleId IdType="pubmed">23489938</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salvadori S, Martinelli G, Zier K. Resection of solid tumors reverses T cell defects and restores protective immunity. J Immunol. 2000;164:2214–2220.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10657677</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bayne LJ, et al.  Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell. 2012;21:822–835.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3575028</ArticleId>
            <ArticleId IdType="pubmed">22698406</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Younos I, et al.  Tumor- and organ-dependent infiltration by myeloid-derived suppressor cells. Int Immunopharmacol. 2011;11:814–826.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21376153</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dolcetti L, et al.  Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur J Immunol. 2010;40:22–35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19941314</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Waight JD, Hu Q, Miller A, Liu S, Abrams SI. Tumor-Derived G-CSF Facilitates Neoplastic Growth through a Granulocytic Myeloid-Derived Suppressor Cell-Dependent Mechanism. PLoS One. 2011;6:e27690.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3218014</ArticleId>
            <ArticleId IdType="pubmed">22110722</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kowanetz M, et al.  Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes. Proc Natl Acad Sci U S A. 2010;107:21248–21255.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3003076</ArticleId>
            <ArticleId IdType="pubmed">21081700</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pekarek LA, Starr BA, Toledano AY, Schreiber H. Inhibition of tumor growth by elimination of granulocytes. J Exp Med. 1995;181:435–440.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2191807</ArticleId>
            <ArticleId IdType="pubmed">7807024</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li H, Han Y, Guo Q, Zhang M, Cao X. Cancer-Expanded Myeloid-Derived Suppressor Cells Induce Anergy of NK Cells through Membrane-Bound TGF-{beta}1. J Immunol. 2009;182:240–249.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19109155</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abe F, et al.  Myeloid-derived suppressor cells in mammary tumor progression in FVB Neu transgenic mice. Cancer Immunol Immunother. 2010;59:47–62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19449184</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lappat EJ, Cawein M. A Study of the Leukemoid Response to Transplantable a-280 Tumor in Mice. Cancer Res. 1964;24:302–311.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14115699</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee MY, Rosse C. Depletion of lymphocyte subpopulations in primary and secondary lymphoid organs of mice by a transplanted granulocytosis-inducing mammary carcinoma. Cancer Res. 1982;42:1255–1260.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7060002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsuchiya Y, Igarashi M, Suzuki R, Kumagai K. Production of colony-stimulating factor by tumor cells and the factor-mediated induction of suppressor cells. J Immunol. 1988;141:699–708.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2968407</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bennett JA, Mitchell MS. Induction of suppressor cells by intravenous administration of Bacillus Calmette-Guerin and its modulation by cyclophosphamide. Biochem Pharmacol. 1979;28:1947–1952.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">313210</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wren SM, Wepsic HT, Larson CH, De Silva MA, Mizushima Y. Inhibition of the graft-versus-host response by BCGcw-induced suppressor cells or prostaglandin E1. Cell Immunol. 1983;76:361–371.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6220811</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Predina JD, et al.  Cytoreduction surgery reduces systemic myeloid suppressor cell populations and restores intratumoral immunotherapy effectiveness. J Hematol Oncol. 2012;5:34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3418164</ArticleId>
            <ArticleId IdType="pubmed">22742411</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Delano MJ, et al.  MyD88-dependent expansion of an immature GR-1(+)CD11b(+) population induces T cell suppression and Th2 polarization in sepsis. J Exp Med. 2007;204:1463–1474.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2118626</ArticleId>
            <ArticleId IdType="pubmed">17548519</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oseroff A, Okada S, Strober S. Natural suppressor (NS) cells found in the spleen of neonatal mice and adult mice given total lymphoid irradiation (TLI) express the null surface phenotype. J Immunol. 1984;132:101–110.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6228575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Young MR, Wright MA. Myelopoiesis-associated immune suppressor cells in mice bearing metastatic Lewis lung carcinoma tumors: Gamma-interferon plus tumor necrosis factor-alpha synergistically reduces immune suppressor and tumor growth-promoting activities of bone marrow cells and diminishes tumor recurrence and metastasis. Cancer Res. 1992;52:6335–6340.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1423279</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kusmartsev SA, Li Y, Chen SH. Gr-1+ myeloid cells derived from tumor-bearing mice inhibit primary T cell activation induced through CD3/CD28 costimulation. J Immunol. 2000;165:779–785.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10878351</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gabrilovich D, et al.  Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood. 1998;92:4150–4166.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9834220</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Watson GA, Fu YX, Lopez DM. Splenic macrophages from tumor-bearing mice co-expressing MAC-1 and MAC-2 antigens exert immunoregulatory functions via two distinct mechanisms. J Leukoc Biol. 1991;49:126–138.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1991996</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Craddock CF, et al.  Circulating stem cells in mice treated with cyclophosphamide. Blood. 1992;80:264–269.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1611093</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sy MS, Miller SD, Claman HN. Immune suppression with supraoptimal doses of antigen in contact sensitivity. I. Demonstration of suppressor cells and their sensitivity to cyclophosphamide. J Immunol. 1977;119:240–244.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">68972</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hooper DC, Hoskin DW, Gronvik KO, Murgita RA. Murine neonatal spleen contains natural T and non-T suppressor cells capable of inhibiting adult alloreactive and newborn autoreactive T-cell proliferation. Cell Immunol. 1986;99:461–475.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2944626</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pak AS, et al.  Mechanisms of immune suppression in patients with head and neck cancer: presence of CD34(+) cells which suppress immune functions within cancers that secrete granulocyte-macrophage colony-stimulating factor. Clin Cancer Res. 1995;1:95–103.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9815891</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Young MRI, Young ME, Wright MA. Stimulation of immune-suppressive bone marrow cells by colony-stimulating factors. Exp Hematol. 1990;18:806–811.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2143138</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bronte V, et al.  Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation. J Immunol. 1999;162:5728–5737.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2228333</ArticleId>
            <ArticleId IdType="pubmed">10229805</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Serafini P, et al.  High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res. 2004;64:6337–6343.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15342423</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shojaei F, et al.  G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc Natl Acad Sci USA. 2009;106:6742–6747.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2665197</ArticleId>
            <ArticleId IdType="pubmed">19346489</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Talmadge JE. Pathways Mediating the Expansion and Immunosuppressive Activity of Myeloid-Derived Suppressor Cells and Their Relevance to Cancer Therapy. Clin Cancer Res. 2007;13:5243–5248.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17875751</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boutte AM, McDonald WH, Shyr Y, Yang L, Lin PC. Characterization of the MDSC proteome associated with metastatic murine mammary tumors using label-free mass spectrometry and shotgun proteomics. PLoS One. 2011;6:e22446.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3154190</ArticleId>
            <ArticleId IdType="pubmed">21853032</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chornoguz O, et al.  Proteomic pathway analysis reveals inflammation increases myeloid-derived suppressor cell resistance to apoptosis. Mol Cell Proteomics. 2011;10:M110 002980.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3047151</ArticleId>
            <ArticleId IdType="pubmed">21191032</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bronte V, Serafini P, Apolloni E, Zanovello P. Tumor-induced immune dysfunctions caused by myeloid suppressor cells. J Immunother. 2001;24:431–446.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11759067</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gabrilovich DI, Velders MP, Sotomayor EM, Kast WM. Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. J Immunol. 2001;166:5398–5406.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11313376</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bronte V, et al.  Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells. J Immunol. 1998;161:5313–5320.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2239007</ArticleId>
            <ArticleId IdType="pubmed">9820504</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Young MR, Wright MA, Matthews JP, Malik I, Prechel M. Suppression of T cell proliferation by tumor-induced granulocyte-macrophage progenitor cells producing transforming growth factor-beta and nitric oxide. J Immunol. 1996;156:1916–1922.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8596044</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gabrilovich DI, et al.  The Terminology Issue for Myeloid-Derived Suppressor Cells. Cancer Res. 2007;67:425–425.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1941787</ArticleId>
            <ArticleId IdType="pubmed">17210725</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang R, Roden RBS. The Terminology Issue for Myeloid-Derived Suppressor Cells. Cancer Res. 2007;67:426–426.</Citation>
        </Reference>
        <Reference>
          <Citation>Ribechini E, Greifenberg V, Sandwick S, Lutz MB. Subsets, expansion and activation of myeloid-derived suppressor cells. Medical Microbiology and Immunology. 2010;199:273–281.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20376485</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Youn JI, Nagaraj S, Collazo M, Gabrilovich DI. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J.Immunol. 2008;181:5791–5802.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2575748</ArticleId>
            <ArticleId IdType="pubmed">18832739</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karsunky H, Merad M, Cozzio A, Weissman IL, Manz MG. Flt3 ligand regulates dendritic cell development from Flt3+ lymphoid and myeloid-committed progenitors to Flt3+ dendritic cells in vivo. J Exp Med. 2003;198:305–313.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2194067</ArticleId>
            <ArticleId IdType="pubmed">12874263</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Movahedi K, et al.  Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res. 2010;70:5728–5739.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20570887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9:162–174.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2828349</ArticleId>
            <ArticleId IdType="pubmed">19197294</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sawanobori Y, et al.  Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice. Blood. 2008;111:5457–5466.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18375791</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Virtuoso LP, et al.  Characterization of iNOS+ Neutrophil-like ring cell in tumor-bearing mice. J Transl Med. 2012;10:152.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3478162</ArticleId>
            <ArticleId IdType="pubmed">22846631</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sasmono RT, et al.  Mouse neutrophilic granulocytes express mRNA encoding the macrophage colony-stimulating factor receptor (CSF-1R) as well as many other macrophage-specific transcripts and can transdifferentiate into macrophages in vitro in response to CSF-1. J Leukoc Biol. 2007;82:111–123.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17438263</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Movahedi K, et al.  Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood. 2008;111:4233–4244.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18272812</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haile LA, Gamrekelashvili J, Manns MP, Korangy F, Greten TF. CD49d is a new marker for distinct myeloid-derived suppressor cell subpopulations in mice. J Immunol. 2010;185:203–210.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20525890</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brandau S, Moses K, Lang S. The kinship of neutrophils and granulocytic myeloid-derived suppressor cells in cancer: Cousins, siblings or twins? Semin Cancer Biol. 2013;23:171–182.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23459190</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mielcarek M, Martin PJ, Torok-Storb B. Suppression of alloantigen-induced T-cell proliferation by CD14+ cells derived from granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells. Blood. 1997;89:1629–1634.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9057645</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Talmadge J, et al.  Immunologic attributes of cytokine mobilized peripheral blood stem cells and recovery following transplantation. Bone Marrow Transplantation. 1996;17:101–109.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8673041</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh RK, et al.  Fas-FasL-mediated CD4+ T-cell apoptosis following stem cell transplantation. Cancer Res. 1999;59:3107–3111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10397252</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wanebo HJ, et al.  Indomethacin sensitive suppressor-cell activity in head and neck cancer patients. The role of the adherent mononuclear cell. Cancer. 1988;61:462–474.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2962730</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ko JS, et al.  Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res. 2009;15:2148–2157.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19276286</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Laoui D, et al.  Mononuclear phagocyte heterogeneity in cancer: different subsets and activation states reaching out at the tumor site. Immunobiology. 2011;216:1192–1202.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21803441</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Youn JI, Gabrilovich DI. The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. Eur J Immunol. 2010;40:2969–2975.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3277452</ArticleId>
            <ArticleId IdType="pubmed">21061430</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lathers DM, Clark JI, Achille NJ, Young MR. Phase IB study of 25-hydroxyvitamin D(3) treatment to diminish suppressor cells in head and neck cancer patients. Hum Immunol. 2001;62:1282–1293.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11704292</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Almand B, et al.  Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol. 2001;166:678–689.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11123353</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zea AH, et al.  Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res. 2005;65:3044–3048.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15833831</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Poschke I, Mougiakakos D, Hansson J, Masucci GV, Kiessling R. Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res. 2010;70:4335–4345.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20484028</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Filipazzi P, et al.  Identification of a New Subset of Myeloid Suppressor Cells in Peripheral Blood of Melanoma Patients With Modulation by a Granulocyte-Macrophage Colony-Stimulation Factor-Based Antitumor Vaccine. J Clin Oncol. 2007;25:2546–2553.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17577033</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodriguez PC, et al.  Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res. 2009;69:1553–1560.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2900845</ArticleId>
            <ArticleId IdType="pubmed">19201693</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dumitru CA, Moses K, Trellakis S, Lang S, Brandau S. Neutrophils and granulocytic myeloid-derived suppressor cells: immunophenotyping, cell biology and clinical relevance in human oncology. Cancer Immunol Immunother. 2012;61:1155–1167.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22692756</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao F, et al.  S100A9 a new marker for monocytic human myeloid-derived suppressor cells. Immunology. 2012;136:176–183.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3403264</ArticleId>
            <ArticleId IdType="pubmed">22304731</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mantovani A, Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol. 2010;22:231–237.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20144856</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Glasser L, Fiederlein RL. Functional differentiation of normal human neutrophils. Blood. 1987;69:937–944.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3814822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DuPre SA, Hunter KW., Jr Murine mammary carcinoma 4T1 induces a leukemoid reaction with splenomegaly: association with tumor-derived growth factors. Exp Mol Pathol. 2007;82:12–24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16919266</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sica A, Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest. 2007;117:1155–1166.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1857267</ArticleId>
            <ArticleId IdType="pubmed">17476345</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sade-Feldman M, et al.  Tumor Necrosis Factor-alpha Blocks Differentiation and Enhances Suppressive Activity of Immature Myeloid Cells during Chronic Inflammation. Immunity. 2013;38:541–554.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23477736</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng P, et al.  Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med. 2008;205:2235–2249.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2556797</ArticleId>
            <ArticleId IdType="pubmed">18809714</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nagaraj S, Gabrilovich DI. Myeloid-derived suppressor cells in human cancer. Cancer J. 2010;16:348–353.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20693846</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ostrand-Rosenberg S, Sinha P. Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer. J Immunol. 2009;182:4499–4506.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2810498</ArticleId>
            <ArticleId IdType="pubmed">19342621</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gibb DR, Saleem SJ, Kang DJ, Subler MA, Conrad DH. ADAM10 overexpression shifts lympho- and myelopoiesis by dysregulating site 2/site 3 cleavage products of Notch. J Immunol. 2011;186:4244–4252.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7365260</ArticleId>
            <ArticleId IdType="pubmed">21368228</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Song X, et al.  CD11b+/Gr-1+ immature myeloid cells mediate suppression of T cells in mice bearing tumors of IL-1beta-secreting cells. J Immunol. 2005;175:8200–8208.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16339559</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Young MR, Wright MA, Young ME. Antibodies to colony-stimulating factors block Lewis lung carcinoma cell stimulation of immune-suppressive bone marrow cells. Cancer Immunol.Immunother. 1991;33:146–152.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1675153</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Y, et al.  MicroRNA-494 Is Required for the Accumulation and Functions of Tumor-Expanded Myeloid-Derived Suppressor Cells via Targeting of PTEN. J Immunol. 2012;188:5500–5510.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22544933</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Almand B, et al.  Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res. 2000;6:1755–1766.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10815894</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Melani C. Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood. 2003;102:2138–2145.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12750171</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pan PY, et al.  Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. Blood. 2008;111:219–228.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2200807</ArticleId>
            <ArticleId IdType="pubmed">17885078</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Solheim J, et al.  Spleen but not tumor infiltration by dendritic and T cells is increased by intravenous adenovirus-Flt3 ligand injection. Cancer Gene Ther. 2007;14:364–371.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17235356</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morales JK, Kmieciak M, Knutson KL, Bear HD, Manjili MH. GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1- bone marrow progenitor cells into myeloid-derived suppressor cells. Breast Cancer Res Treat. 2010;123:39–49.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3095485</ArticleId>
            <ArticleId IdType="pubmed">19898981</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ko JS, et al.  Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res. 2010;70:3526–3536.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3426924</ArticleId>
            <ArticleId IdType="pubmed">20406969</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Priceman SJ, et al.  Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy. Blood. 2010;115:1461–1471.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2826767</ArticleId>
            <ArticleId IdType="pubmed">20008303</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DeNardo DG, et al.  Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy. Cancer Discov. 2011;1:54–67.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3203524</ArticleId>
            <ArticleId IdType="pubmed">22039576</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fricke I, et al.  Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses. Clin Cancer Res. 2007;13:4840–4848.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17699863</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Panopoulos AD, Watowich SS. Granulocyte colony-stimulating factor: molecular mechanisms of action during steady state and 'emergency' hematopoiesis. Cytokine. 2008;42:277–288.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2852428</ArticleId>
            <ArticleId IdType="pubmed">18400509</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rutella S, Zavala F, Danese S, Kared H, Leone G. Granulocyte colony-stimulating factor: a novel mediator of T cell tolerance. J Immunol. 2005;175:7085–7091.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16301609</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kyo S, Kanaya T, Takakura M, Inoue M. A case of cervical cancer with aggressive tumor growth: possible autocrine growth stimulation by G-CSF and Il-6. Gynecol Oncol. 2000;78:383–387.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10985899</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Okazaki T, et al.  Granulocyte colony-stimulating factor promotes tumor angiogenesis via increasing circulating endothelial progenitor cells and Gr1+CD11b+ cells in cancer animal models. Int Immunol. 2006;18:1–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16352631</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bronte V, Zanovello P. Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol. 2005;5:641–654.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16056256</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peranzoni E, et al.  Myeloid-derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol. 2010;22:238–244.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20171075</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Young MR, Young ME, Wright MA. Myelopoiesis-associated suppressor-cell activity in mice with Lewis lung carcinoma tumors: interferon-gamma plus tumor necrosis factor-alpha synergistically reduce suppressor cell activity. Int.J.Cancer. 1990;46:245–250.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2143498</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Choi KL, Maier T, Holda JH, Claman HN. Suppression of cytotoxic T-cell generation by natural suppressor cells from mice with GVHD is partially reversed by indomethacin. Cell Immunol. 1988;112:271–278.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2965616</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schlecker E, et al.  Tumor-Infiltrating Monocytic Myeloid-Derived Suppressor Cells Mediate CCR5-Dependent Recruitment of Regulatory T Cells Favoring Tumor Growth. J Immunol. 2012;189:5602–5611.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23152559</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Youn JI, Collazo M, Shalova IN, Biswas SK, Gabrilovich DI. Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice. J Leukoc Biol. 2012;91:167–181.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3250305</ArticleId>
            <ArticleId IdType="pubmed">21954284</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mirza N. All-trans-Retinoic Acid Improves Differentiation of Myeloid Cells and Immune Response in Cancer Patients. Cancer Res. 2006;66:9299–9307.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1586106</ArticleId>
            <ArticleId IdType="pubmed">16982775</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kusmartsev S, et al.  All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res. 2003;63:4441–4449.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12907617</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Young MRI, et al.  1-alpha,25-dihydroxyvitamin D3 plus gamma-interferon blocks lung tumor production of granulocyte-macrophage colony-stimulating factor and induction of immunosuppressor cells. Cancer Res. 1993;53:6006–6006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8261414</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sinha P, et al.  Proinflammatory s100 proteins regulate the accumulation of myeloid-derived suppressor cells. J Immunol. 2008;181:4666–4675.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2810501</ArticleId>
            <ArticleId IdType="pubmed">18802069</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang L, et al.  Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell. 2004;6:409–421.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15488763</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zon LI. Intrinsic and extrinsic control of haematopoietic stem-cell self-renewal. Nature. 2008;453:306–313.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18480811</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Si Y, Tsou CL, Croft K, Charo IF. CCR2 mediates hematopoietic stem and progenitor cell trafficking to sites of inflammation in mice. J Clin Invest. 2010;120:1192–1203.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2846049</ArticleId>
            <ArticleId IdType="pubmed">20234092</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johns JL, Christopher MM. Extramedullary hematopoiesis: a new look at the underlying stem cell niche, theories of development, and occurrence in animals. Vet Pathol. 2012;49:508–523.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22262354</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pruijt JF, Willemze R, Fibbe WE. Mechanisms underlying hematopoietic stem cell mobilization induced by the CXC chemokine interleukin-8. Curr Opin Hematol. 1999;6:152–158.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10226735</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Demetri GD, Griffin JD. Granulocyte colony-stimulating factor and its receptor. Blood. 1991;78:2791–2808.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1720034</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Price TH, Chatta GS, Dale DC. Effect of recombinant granulocyte colony-stimulating factor on neutrophil kinetics in normal young and elderly humans. Blood. 1996;88:335–340.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8704192</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nefedova Y. Regulation of Dendritic Cell Differentiation and Antitumor Immune Response in Cancer by Pharmacologic-Selective Inhibition of the Janus-Activated Kinase 2/Signal Transducers and Activators of Transcription 3 Pathway. Cancer Res. 2005;65:9525–9535.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1351362</ArticleId>
            <ArticleId IdType="pubmed">16230418</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Levesque JP, Hendy J, Takamatsu Y, Simmons PJ, Bendall LJ. Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. J Clin Invest. 2003;111:187–196.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC151860</ArticleId>
            <ArticleId IdType="pubmed">12531874</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lévesque J-P, et al.  Mobilization by either cyclophosphamide or granulocyte colony-stimulating factor transforms the bone marrow into a highly proteolytic environment. Exp Hematol. 2002;30:440–449.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12031650</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Link DC. Neutrophil homeostasis: a new role for stromal cell-derived factor-1. Immunol Res. 2005;32:169–178.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16106067</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nagasawa T, et al.  Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature. 1996;382:635–638.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8757135</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McQuibban GA. Matrix Metalloproteinase Activity Inactivates the CXC Chemokine Stromal Cell-derived Factor-1. J Biol Chem. 2001;276:43503–43508.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11571304</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luster AD, Alon R, von Andrian UH. Immune cell migration in inflammation: present and future therapeutic targets. Nat Immunol. 2005;6:1182–1190.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16369557</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ueno T, et al.  Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res. 2000;6:3282–3289.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10955814</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Watanabe T, et al.  GM-CSF-mobilized peripheral blood CD34+ cells differ from steady- state bone marrow CD34+ cells in adhesion molecule expression. Bone Marrow Transplant. 1997;19:1175–1181.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9208110</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pruijt JF, et al.  Anti-LFA-1 blocking antibodies prevent mobilization of hematopoietic progenitor cells induced by interleukin-8. Blood. 1998;91:4099–4105.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9596655</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jin H, Su J, Garmy-Susini B, Kleeman J, Varner J. Integrin α4β1 Promotes Monocyte Trafficking and Angiogenesis in Tumors. Cancer Res. 2006;66:2146–2152.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16489015</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jin H, et al.  A homing mechanism for bone marrow-derived progenitor cell recruitment to the neovasculature. J Clin Invest. 2006;116:652–662.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1378185</ArticleId>
            <ArticleId IdType="pubmed">16498499</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jin F, et al.  Degradation of BM SDF-1 by MMP-9: the role in G-CSF-induced hematopoietic stem/progenitor cell mobilization. Bone Marrow Transplant. 2008;42:581–588.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18679363</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chavakis E, et al.  Role of beta2-integrins for homing and neovascularization capacity of endothelial progenitor cells. J Exp Med. 2005;201:63–72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2212777</ArticleId>
            <ArticleId IdType="pubmed">15623573</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Youn JI, et al.  Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer. Nat Immunol. 2013</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3578019</ArticleId>
            <ArticleId IdType="pubmed">23354483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Connolly MK, et al.  Distinct populations of metastases-enabling myeloid cells expand in the liver of mice harboring invasive and preinvasive intra-abdominal tumor. J Leukoc Biol. 2010;87:713–725.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2858308</ArticleId>
            <ArticleId IdType="pubmed">20042467</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Santo C. Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. Proc Natl Acad Sci. 2005;102:4185–4190.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC554823</ArticleId>
            <ArticleId IdType="pubmed">15753302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ellies LG, et al.  Mammary tumor latency is increased in mice lacking the inducible nitric oxide synthase. Int J Cancer. 2003;106:1–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12794750</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun HL, et al.  Increased frequency and clinical significance of myeloid-derived suppressor cells in human colorectal carcinoma. World J Gastroenterol. 2012;18:3303–3309.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3391769</ArticleId>
            <ArticleId IdType="pubmed">22783056</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paget S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev. 1989;8:98–101.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2673568</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Balwit JM, Hwu P, Urba WJ, Marincola FM. The iSBTc/SITC primer on tumor immunology and biological therapy of cancer: a summary of the 2010 program. J Transl Med. 2011;9:18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3038923</ArticleId>
            <ArticleId IdType="pubmed">21281484</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sumida K, et al.  Anti-IL-6 receptor mAb eliminates myeloid-derived suppressor cells and inhibits tumor growth by enhancing T-cell responses. Eur J Immunol. 2012;42:2060–2072.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22653638</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vincent J, et al.  5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 2010;70:3052–3061.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20388795</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kodumudi KN, et al.  A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin Cancer Res. 2010;16:4583–4594.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3874864</ArticleId>
            <ArticleId IdType="pubmed">20702612</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Serafini P, et al.  Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med. 2006;203:2691–2702.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2118163</ArticleId>
            <ArticleId IdType="pubmed">17101732</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suzuki E. Gemcitabine Selectively Eliminates Splenic Gr-1+/CD11b+ Myeloid Suppressor Cells in Tumor-Bearing Animals and Enhances Antitumor Immune Activity. Clin Cancer Res. 2005;11:6713–6721.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16166452</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Antonia SJ, et al.  Combination of p53 Cancer Vaccine with Chemotherapy in Patients with Extensive Stage Small Cell Lung Cancer. Clin Cancer Res. 2006;12:878–887.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16467102</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mukherjee P, et al.  Progression of Pancreatic Adenocarcinoma Is Significantly Impeded with a Combination of Vaccine and COX-2 Inhibition. J Immunol. 2009;182:216–224.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3838792</ArticleId>
            <ArticleId IdType="pubmed">19109152</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stenvold H, et al.  Overexpression of matrix metalloproteinase-7 and-9 in NSCLC tumor and stromal cells: correlation with a favorable clinical outcome. Lung Cancer. 2012;75:235–241.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21764478</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Corzo CA, et al.  HIF-1alpha regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med. 2010;207:2439–2453.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2964584</ArticleId>
            <ArticleId IdType="pubmed">20876310</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Du R, et al.  HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell. 2008;13:206–220.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2643426</ArticleId>
            <ArticleId IdType="pubmed">18328425</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang L, et al.  Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell. 2008;13:23–35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2245859</ArticleId>
            <ArticleId IdType="pubmed">18167337</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Forrester E, et al.  Effect of conditional knockout of the type II TGF-beta receptor gene in mammary epithelia on mammary gland development and polyomavirus middle T antigen induced tumor formation and metastasis. Cancer Res. 2005;65:2296–2302.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15781643</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fidler IJ. Metastasis: Quantitative Analysis of Distribution and Fate of Tumor Emboli Labeled With 1251-5-lodo-2'-deoxyuridine1,2,3. J Natl Cancer Inst. 1970;45:773–782.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">5513503</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fidler IJ, Gersten DM, Hart IR. The biology of cancer invasion and metastasis. Adv Cancer Res. 1978;28:149–250.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">360795</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hart IR, Fidler IJ. Role of organ selectivity in the determination of metastatic patterns of B16 melanoma. Cancer Res. 1980;40:2281–2287.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7388794</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Psaila B, Lyden D. The metastatic niche: adapting the foreign soil. Nat Rev Cancer. 2009;9:285–293.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3682494</ArticleId>
            <ArticleId IdType="pubmed">19308068</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaplan RN, Rafii S, Lyden D. Preparing the"Soil": The Premetastatic Niche. Cancer Research. 2006;66:11089–11093.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2952469</ArticleId>
            <ArticleId IdType="pubmed">17145848</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Talmadge JE, Fidler IJ. AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Res. 2010;70:5649–5669.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4037932</ArticleId>
            <ArticleId IdType="pubmed">20610625</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nishie A, et al.  Macrophage infiltration and heme oxygenase-1 expression correlate with angiogenesis in human gliomas. Clinical Cancer Research. 1999;5:1107–1113.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10353745</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Asahara T, et al.  Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997;275:964–967.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9020076</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mauro E, et al.  Mobilization of endothelial progenitor cells in patients with hematological malignancies after treatment with filgrastim and chemotherapy for autologous transplantation. Eur J Haematol. 2007;78:374–380.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17331127</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nolan DJ, et al.  Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization. Genes Dev. 2007;21:1546–1558.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1891431</ArticleId>
            <ArticleId IdType="pubmed">17575055</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Davidoff AM, et al.  Bone marrow-derived cells contribute to tumor neovasculature and, when modified to express an angiogenesis inhibitor, can restrict tumor growth in mice. Clin Cancer Res. 2001;7:2870–2879.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11555605</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dome B. Identification and Clinical Significance of Circulating Endothelial Progenitor Cells in Human Non-Small Cell Lung Cancer. Cancer Res. 2006;66:7341–7347.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16849585</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Young MR, Kolesiak K, Wright MA, Gabrilovich DI. Chemoattraction of femoral CD34+ progenitor cells by tumor-derived vascular endothelial cell growth factor. Clin Exp Metastasis. 1999;17:881–888.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11089887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mulligan JK, Rosenzweig SA, Young MR. Tumor secretion of VEGF induces endothelial cells to suppress T cell functions through the production of PGE2. J Immunother. 2010;33:126–135.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3333835</ArticleId>
            <ArticleId IdType="pubmed">20145550</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Madlambayan GJ, et al.  Bone marrow stem and progenitor cell contribution to neovasculogenesis is dependent on model system with SDF-1 as a permissive trigger. Blood. 2009;114:4310–4319.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2774559</ArticleId>
            <ArticleId IdType="pubmed">19717647</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li B, et al.  Low levels of tumor necrosis factor alpha increase tumor growth by inducing an endothelial phenotype of monocytes recruited to the tumor site. Cancer Res. 2009;69:338–348.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2651676</ArticleId>
            <ArticleId IdType="pubmed">19118019</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Asahara T, et al.  VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J. 1999;18:3964–3972.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1171472</ArticleId>
            <ArticleId IdType="pubmed">10406801</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lyden D, et al.  Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med. 2001;7:1194–1201.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11689883</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene. 2008;27:5904–5912.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3689267</ArticleId>
            <ArticleId IdType="pubmed">18836471</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Whiteside TL. Tricks tumors use to escape from immune control. Oral Oncol. 2009;45:e119–e123.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19467917</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Montero AJ, Diaz-Montero CM, Kyriakopoulos CE, Bronte V, Mandruzzato S. Myeloid-derived suppressor cells in cancer patients: a clinical perspective. J Immunother. 2012;35:107–115.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22306898</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Poschke I, Kiessling R. On the armament and appearances of human myeloid-derived suppressor cells. Clin Immunol. 2012;144:250–268.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22858650</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer. 2009;9:239–252.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3251309</ArticleId>
            <ArticleId IdType="pubmed">19279573</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mazzoni A, et al.  Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J Immunol. 2002;168:689–695.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11777962</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodriguez PC, et al.  Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res. 2004;64:5839–5849.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15313928</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nagaraj S, Schrum AG, Cho HI, Celis E, Gabrilovich DI. Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. J Immunol. 2010;184:3106–3116.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2832724</ArticleId>
            <ArticleId IdType="pubmed">20142361</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu L, et al.  Inhibition of PPARgamma in myeloid-lineage cells induces systemic inflammation, immunosuppression, and tumorigenesis. Blood. 2012;119:115–126.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3251224</ArticleId>
            <ArticleId IdType="pubmed">22053106</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wolf AM, et al.  The effect of zoledronic acid on the function and differentiation of myeloid cells. Haematologica. 2006;91:1165–1171.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16956814</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Talmadge JE, et al.  Chemoprevention by cyclooxygenase-2 inhibition reduces immature myeloid suppressor cell expansion. Int Immunopharmacol. 2007;7:140–151.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17178380</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van Cruijsen H, et al.  Sunitinib-Induced Myeloid Lineage Redistribution in Renal Cell Cancer Patients: CD1c+ Dendritic Cell Frequency Predicts Progression-Free Survival. Clin Cancer Res. 2008;14:5884–5892.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18794101</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shojaei F, et al.  Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature. 2007;450:825–831.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18064003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang D, et al.  Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res. 2010;70:1063–1071.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3719378</ArticleId>
            <ArticleId IdType="pubmed">20103651</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shojaei F, et al.  Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nature Biotechnol. 2007;25:911–920.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17664940</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Finke J, et al.  MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. Int Immunopharmacol. 2011</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3109226</ArticleId>
            <ArticleId IdType="pubmed">21315783</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;473:298–307.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4049445</ArticleId>
            <ArticleId IdType="pubmed">21593862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fischer C, Mazzone M, Jonckx B, Carmeliet P. FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? Nat Rev Cancer. 2008;8:942–956.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19029957</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu L, et al.  Direct Evidence that Bevacizumab, an Anti-VEGF Antibody, Up-regulates SDF1α, CXCR4, CXCL6, and Neuropilin 1 in Tumors from Patients with Rectal Cancer. Cancer Res. 2009;69:7905–7910.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2859041</ArticleId>
            <ArticleId IdType="pubmed">19826039</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Filipazzi P, Huber V, Rivoltini L. Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients. Cancer Immunol Immunother. 2012;61:255–263.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22120756</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Greten TF, Manns MP, Korangy F. Myeloid derived suppressor cells in human diseases. Int Immunopharmacol. 2011</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3478130</ArticleId>
            <ArticleId IdType="pubmed">21237299</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang J, Patel L, Pienta KJ. CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. Cytokine &amp; Growth Factor Reviews. 2010;21:41–48.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2857769</ArticleId>
            <ArticleId IdType="pubmed">20005149</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Melani C, Sangaletti S, Barazzetta FM, Werb Z, Colombo MP. Amino-Biphosphonate Mediated MMP-9 Inhibition Breaks the Tumor-Bone Marrow Axis Responsible for Myeloid-Derived Suppressor Cell Expansion and Macrophage Infiltration in Tumor Stroma. Cancer Res. 2007;67:11438–11446.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2646404</ArticleId>
            <ArticleId IdType="pubmed">18056472</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
